The University of the Philippines Manila (UPM) signs its first license agreement for the technology of Lagundi pediatric syrup with Azarias Pharmaceutical Laboratories, Inc. last January 24, 2010.
Per the Resolution of its Board of Regents (BOR) on October 2010, UP Manila adopted the evaluation and recommendation of PCHRD to approve the license application of Azarias based on the policies and guidelines of the DOST.
In his acceptance message, Project Operations Head of the Azarias Pharmaceutical Laboratories, Inc., Engr. Jaime Joel C. Monje said, “The therapeutic effects of Lagundi is indeed a testimony that the indigenous medicinal products developed in the Philippines can very well compete with the more established preparations coming from imported pharmaceutical companies. Our many thanks to UP Manila and to the office of the PCHRD, for making this long awaited event to be a reality.”
Concluding the signing ceremony, Professor Zorayda E. Leopando, Vice Chancellor for Planning and Development, UP Manila stated, “This pioneering partnership with Azarias Pharmaceutical Laboratories Inc. is our proactive and committed response in the implementation of the Philippine Technology Transfer Act of 2009.”
Together with UP Manila’s signing of the license agreement with Azarias Pharmaceutical Laboratories Inc., PCHRD, also signed the formal transfer of technology entitlement on medicinal plant products generated from National Integrated Research on Philippine Medicinal Plants (NIRPROMP) researches to UP Manila in accordance with RA 10055. Rachel Ann Doreen D. Nadal, PCHRD
